VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
This Quarter Return
-19.25%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$585M
AUM Growth
+$585M
(-34%)
Cap. Flow
-$154M
Cap. Flow
% of AUM
-26.37%
Top 10 Holdings %
Top 10 Hldgs %
61.33%
Holding
425
New
84
Increased
85
Reduced
101
Closed
119
Top Buys
| 1 |
Energy Transfer Partners
ET
|
$43.7M |
| 2 |
Enterprise Products Partners
EPD
|
$7.86M |
| 3 |
Oneok
OKE
|
$7.26M |
| 4 |
PSXP
PHILLIPS 66 PARTNERS LP
PSXP
|
$2.37M |
| 5 |
AM
ANTERO MIDSTREAM PARTNERS LP
AM
|
$2.31M |
Top Sells
| 1 |
ETP
Energy Transfer Partners, L.P.
ETP
|
$77.3M |
| 2 |
Marathon Petroleum
MPC
|
$24.9M |
| 3 |
EEP
Enbridge Energy Partners
EEP
|
$23.6M |
| 4 |
Phillips 66
PSX
|
$14.9M |
| 5 |
Williams Companies
WMB
|
$14.7M |
Sector Composition
| 1 | Energy | 82.73% |
| 2 | Healthcare | 7.29% |
| 3 | Utilities | 2.06% |
| 4 | Financials | 0.12% |
| 5 | Technology | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
UBX
101
DELISTED
Unity Biotechnology
UBX
| $309K | 0.05% | +18,987 | New | +$309K |
|
|
MRTX
102
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $309K | 0.05% | 7,284 -2,291 | -24% | -$97.2K |
|
103
CytomX Therapeutics
CTMX
$336M
| $308K | 0.05% | 20,415 +1,565 | +8% | +$23.6K |
|
104
Kura Oncology
KURA
$686M
| $308K | 0.05% | 21,970 -3,468 | -14% | -$48.6K |
|
105
uniQure
QURE
$896M
| $308K | 0.05% | 10,678 -2,773 | -21% | -$80K |
|
|
BHVN
106
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $308K | 0.05% | 8,320 -3,305 | -28% | -$122K |
|
107
Denali Therapeutics
DNLI
$2.23B
| $306K | 0.05% | 14,790 -10,928 | -42% | -$226K |
|
108
Savara
SVRA
$567M
| $305K | 0.05% | +40,308 | New | +$305K |
|
109
Madrigal Pharmaceuticals
MDGL
$9.76B
| $304K | 0.05% | 2,700 +1,122 | +71% | +$126K |
|
110
Ascendis Pharma
ASND
$11.8B
| $300K | 0.05% | +4,789 | New | +$300K |
|
111
Sangamo Therapeutics
SGMO
$157M
| $300K | 0.05% | 26,120 -4,015 | -13% | -$46.1K |
|
112
Xencor
XNCR
$580M
| $298K | 0.05% | 8,229 -3,280 | -28% | -$119K |
|
113
PTC Therapeutics
PTCT
$3.92B
| $297K | 0.05% | 8,648 -3,678 | -30% | -$126K |
|
|
SRNE
114
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $297K | 0.05% | 123,823 +61,132 | +98% | +$147K |
|
115
Neuronetics
STIM
$220M
| $296K | 0.05% | +15,272 | New | +$296K |
|
116
Franklin FTSE India ETF
FLIN
$2.28B
| $295K | 0.05% | 13,338 -12,425 | -48% | -$275K |
|
|
FPRX
117
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $292K | 0.05% | 31,427 +4,603 | +17% | +$42.8K |
|
|
BLUE
118
DELISTED
bluebird bio
BLUE
| $291K | 0.05% | 2,934 +524 | +22% | +$52K |
|
119
Rocket Pharmaceuticals
RCKT
$354M
| $291K | 0.05% | 19,604 -2,170 | -10% | -$32.2K |
|
|
GBT
120
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $291K | 0.05% | 7,094 -2,959 | -29% | -$121K |
|
|
XLRN
121
DELISTED
Acceleron Pharma Inc.
XLRN
| $291K | 0.05% | 6,685 -6,419 | -49% | -$279K |
|
|
AKCA
122
DELISTED
Akcea Therapeutics, Inc. Common Stock
AKCA
| $290K | 0.05% | 9,610 -9,819 | -51% | -$296K |
|
|
BPMC
123
DELISTED
Blueprint Medicines
BPMC
| $289K | 0.05% | 5,364 -956 | -15% | -$51.5K |
|
124
Esperion Therapeutics
ESPR
$448M
| $289K | 0.05% | 6,279 -5,018 | -44% | -$231K |
|
125
Exelon
EXC
$44.1B
| $289K | 0.05% | 6,400 | – | – |
|